After peaking at an $6 billion valuation in the public market in 2021, 23andMe filed for bankruptcy in 2025. There’s no repeat incentive for consumers to keep testing their DNA. Plus security breaches impacted 6.9 million users and the data sold to drug developers wasn’t proving valuable enough.
